Statistical methods in oncology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Hazard ratio
Log-rank test
Cochran-Mantel-Haenszel test
Odds ratio
Cox proportional-hazards model
Fisher exact test
Risk difference
Stratified log-rank test
All oncology trials
1,418 results
- A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202): Complete Statistical AnalysisIndependent statistical analysis of A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202): primary endpoint results, effect estimate with confidence interval,…
- A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma: primary endpoint results, effect estimate with confidence…
- A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology: Complete Statistical AnalysisIndependent statistical analysis of A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology: primary endpoint results, effect estimate with confidence interval, sample-size…
- A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG): Complete Statistical AnalysisIndependent statistical analysis of A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS): Complete Statistical AnalysisIndependent statistical analysis of A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial): Complete Statistical AnalysisIndependent statistical analysis of A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial): primary endpoint results, effect…
- A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic…
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702): Complete Statistical AnalysisIndependent statistical analysis of A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003): Complete Statistical AnalysisIndependent statistical analysis of A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003): primary endpoint results, effect estimate with confidence…
- A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients: Complete Statistical AnalysisIndependent statistical analysis of A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients: Complete Statistical AnalysisIndependent statistical analysis of A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients: primary endpoint results, effect estimate with confidence interval, sample-size…
- A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC): Complete Statistical AnalysisIndependent statistical analysis of A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC): primary endpoint results, effect estimate with…
- A Phase I/II Trial of VR-CHOP in Lymphoma Patients: Complete Statistical AnalysisIndependent statistical analysis of A Phase I/II Trial of VR-CHOP in Lymphoma Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00634179).
- A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size…
- A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients…
- A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma: primary…
- A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy: primary endpoint results, effect estimate with confidence interval,…
- A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: primary endpoint results, effect estimate with confidence interval,…
- A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy: primary endpoint results, effect estimate with…
- A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib:…
- A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC): Complete Statistical AnalysisIndependent statistical analysis of A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker…
- A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma: primary endpoint results, effect estimate with…
- A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval,…
- A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor: Complete Statistical AnalysisIndependent statistical analysis of A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor: primary endpoint results,…
- A Phase III Trial For Patients With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Phase III Trial For Patients With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00191152).
- A Pilot Study of Acupuncture Treatment for Dysphagia: Complete Statistical AnalysisIndependent statistical analysis of A Pilot Study of Acupuncture Treatment for Dysphagia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00797732).
- A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL: Complete Statistical AnalysisIndependent statistical analysis of A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Proof-of-principle Study of HBO-SRS for Brain Metastases: Complete Statistical AnalysisIndependent statistical analysis of A Proof-of-principle Study of HBO-SRS for Brain Metastases: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01850563).
- A Prospective, Single-center, Single-arm, Pivotal Trial of the Medtronic Hugo™ Robotic Assisted Surgery (RAS) System: Complete Statistical AnalysisIndependent statistical analysis of A Prospective, Single-center, Single-arm, Pivotal Trial of the Medtronic Hugo™ Robotic Assisted Surgery (RAS) System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study): Complete Statistical AnalysisIndependent statistical analysis of A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck: Complete Statistical AnalysisIndependent statistical analysis of A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck: primary endpoint…